39.40

4.11% 1.65

Protagonist Therapeutics Inc (PTGX)

Overview News Price History Option Chain Financials Why PTGX Down? Discussions Forecast

Protagonist Therapeutics Inc stock is traded at $39.40, with a volume of 285.24K. It is up +4.11% in the last 24 hours and up +2.21% over the past month. Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Previous Close:

$37.75

Open:

$37.81

24h Volume:

285.24K

Relative Volume:

0.45

Market Cap:

$2.25B

Revenue:

$45.48M

Net Income/Loss:

$169.95M

P/E Ratio:

15.04

EPS:

2.62

Net Cash Flow:

$230.85M

1W Performance:

+3.97%

1M Performance:

+2.21%

6M Performance:

+9.81%

1Y Performance:

+54.67%

1-Day Range:

$37.81

$39.49

1-Week Range:

$36.65

$39.42

52-Week Range:

$24.22

$48.89

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name

Protagonist Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(510) 474-0170

Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Employee

126

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

PTGX's Discussions on Twitter

Compare PTGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTGX Protagonist Therapeutics Inc	39.46	2.25B	45.48M	169.95M	230.85M	2.62
VRTX Vertex Pharmaceuticals Inc	472.99	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	718.02	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	654.12	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	276.50	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.43	28.75B	3.30B	-501.07M	1.03B	-2.1146

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Dec-06-24	Initiated	Goldman	Neutral
Nov-05-24	Initiated	Wedbush	Outperform
Sep-24-24	Initiated	TD Cowen	Buy
Sep-09-24	Initiated	Truist	Buy
Oct-30-23	Initiated	CapitalOne	Overweight
May-25-23	Resumed	Jefferies	Buy
Aug-25-22	Initiated	JMP Securities	Mkt Outperform
Feb-11-22	Initiated	BTIG Research	Buy
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral
May-24-21	Initiated	JMP Securities	Mkt Outperform
May-24-21	Initiated	Northland Capital	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight
Sep-18-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Initiated	Jefferies	Buy
May-18-20	Reiterated	H.C. Wainwright	Buy
Jul-08-19	Initiated	H.C. Wainwright	Buy
May-09-19	Upgrade	Stifel	Hold → Buy
Dec-06-18	Initiated	Nomura	Buy
Jan-29-18	Initiated	Stifel	Buy
Jul-21-17	Initiated	BTIG Research	Buy

View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

10:38 AM

Truist maintains Buy on Protagonist Therapeutics with $60 target By Investing.com - Investing.com UK

10:38 AM

04:23 AM

Caprock Group LLC Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

04:23 AM

Feb 06, 2025

Selling Buzz: Protagonist Therapeutics Inc [PTGX] Chief Medical Officer MOLINA ARTURO MD sells 26,000 shares of the company – Knox Daily - Knox Daily

Feb 06, 2025

Financial Metrics Check: Protagonist Therapeutics Inc (PTGX)’s Ratios for Trailing Twelve Months - The Dwinnex

Feb 06, 2025